Project
Characterisation and risk stratification of patient subgroups in dilated cardiomyopathy by utilisation of an inflammatory 47-plex-biomarker panel
- Project term
11/2021 - 02/2023
- Granted budget
€ 40,000
- Research resource used
Resource liquid samples/image data
- Keywords
Inflammatory biomarker, classification, machine learning, DCM, risk stratification
- Principal Investigator
-
Kristin Lehnert, Sabine Ameling (Greifswald University Medicine and Institute Functional Genomics, Clinic and Polyclinic for Internal Medicine B)

Inflammation plays a role in the development of heart failure and dilated cardiomyopathy and cytokines are involved in these processes.
There is a clinical need to identify specific biomarkers to enhance diagnosis, treatment decisions and risk stratification in patients with dilated cardiomyopathy. Following promising first results using 13 markers in a Greifswald patient cohort we currently perform measurements of 47 cytokines in this group. The DZHK biosamples are needed to gain further insight into inflammation mediation and to identify subgroups with distinct patterns to enhance our knowledge of inflammation processes and to validate our preliminary results.
Publications
There are no publications available yet.